Assessment of factors influencing glymphatic activity and implications for clinical medicine
ECC5004 further strengthens our existing pipeline addressing both incretin and non-incretin pathways, including our GLP-1/glucagon dual agonist [AZD9550] and long-acting amylin analogue [AZD6234]. Preliminary results from a Phase I trial in the United States suggest ECC5004 has a different profile from most of the current drugs, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo
How many human participants were included
Our individualized care, competitive pricing, and efficient telehealth services allow you to connect with a healthcare provider within 24 hours
Historical Context and Research In the early 1980s, researchers began exploring the role of gut hormones in regulating blood sugar levels
Peptide Therapeutics CDMO Market Analysis and Forecast by Fact.MR According to Fact.MR estimates, the global peptide therapeutics cdmo market market was valued at USD 2.9 billion in 2025
